1-(4-{2-[6-(2-thiophen-3-yl-ethyl)-pyridazin-3-yl]-ethyl}-benzyl)-piperidin-4-ol trifluoroacetate | 1033704-58-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(4-{2-[6-(2-thiophen-3-yl-ethyl)-pyridazin-3-yl]-ethyl}-benzyl)-piperidin-4-ol trifluoroacetate
• 英文别名: 1-[[4-[2-[6-(2-Thiophen-3-ylethyl)pyridazin-3-yl]ethyl]phenyl]methyl]piperidin-4-ol;2,2,2-trifluoroacetic acid
• CAS: 1033704-58-3
• 化学式: C₂HF₃O₂*C₂₄H₂₉N₃OS
• 分子量: 521.604
• InChiKey: JWOBKHVDZVSIKY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  36
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  115
• 氢给体数：
  2
• 氢受体数：
  10

文献信息

• Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds
  申请人：Lehmann-Lintz Thorsten

  公开号：US20100197908A1

  公开（公告）日：2010-08-05

  The present invention relates to compounds of general formula I wherein the groups and radicals B, W, X, Y, Z, R 1 , R 2 , have the meanings given in claim 1 . Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

  本发明涉及一般式I的化合物，其中基团和基团B、W、X、Y、Z、R1、R2的含义如权利要求书1所述。此外，本发明还涉及含有本发明中至少一种化合物的制药组合物。由于其MCH受体拮抗活性，本发明中的制药组合物适用于治疗代谢性疾病和/或饮食障碍，特别是肥胖症、暴食症、厌食症、暴食症和糖尿病。
• NEW PYRIDAZINE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2102171A1

  公开（公告）日：2009-09-23
• [EN] NEW PYRIDAZINE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS<br/>[FR] NOUVEAUX DÉRIVÉS PYRIDAZINES À ACTIVITÉ ANTAGONISTE DU RÉCEPTEUR MCH ET MÉDICAMENTS COMPRENANT CES COMPOSÉS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2008071646A1

  公开（公告）日：2008-06-19

  [EN] The present invention relates to compounds of general formula I wherein the groups and radicals B, W, X, Y, Z, R¹, R², have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.
  [FR] La présente invention concerne des composés de formule générale (I) dans laquelle les groupes et radicaux B, W, X, Y, Z, R¹, R², sont tels que définis dans la revendication 1. L'invention concerne également des compositions pharmaceutiques contenant au moins un composé selon l'invention. Grâce à leur activité antagoniste du récepteur MCH, les compositions pharmaceutiques selon l'invention sont aptes au traitement de troubles métaboliques et/ou de troubles de l'alimentation, notamment l'obésité, la boulimie, l'anorexie, l'hyperphagie et le diabète.